Biotech News

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.2026-03-12 12:35 ESTClinical readout

SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KURAKura Oncology2026-06-11 12:02 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

IDYAIDEAYA Biosciences2026-06-01 15:00 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

View all latest news

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer. Its story is built around a small set of development assets aimed at difficult tumors.

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-05-14 12:00 EST

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SLSSELLAS Life Sciences Group, Inc.2026-05-12 20:05 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-03-19 20:05 EST

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-03-17 20:30 EST

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

SLSSELLAS Life Sciences Group, Inc.2026-03-12 12:35 EST

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Stock data

Close: 11.70 USD
Market cap: 1.55B USD
Exchange: NASDAQ
Sector: Life Science Tools
Location: United States